Nurix Posts Wider Q2 Net Loss As Revenue Drops; Highlights $700 Million Roche Deal

EarningsCorporate Action
โดย RTTNews·Read original
Summary · why it matters

Nurix Therapeutics reported a wider net loss and lower revenue for its fiscal second quarter ended May 31, 2026, while highlighting a $700 million upfront payment expected from a new collaboration with Roche. Net loss widened to $89.5 million, or $0.81 per share, from $43.5 million, or $0.52 per share, a year earlier. Revenue fell to $9 million from $44.1 million, primarily due to $30 million in license revenue recognized in the prior-year period from two Sanofi license extensions. The company entered into a collaboration with Roche to co-develop and co-commercialize its BTK degrader bexobrutide, with the $700 million upfront payment expected within 30 days and potential total payments of up to $2.3 billion including milestones. Nurix had cash, cash equivalents and marketable securities of $443.5 million as of May 31, 2026, and is continuing enrollment in a pivotal Phase 2 trial of bexobrutide in relapsed/refractory chronic lymphocytic leukemia.

Impact on stocks 3

Health Care▲ · 2 stocks
Roche Holding AG
ROP
▲ PositiveTechnologyrelevance

Roche enters collaboration to co-develop and co-commercialize Nurix's BTK degrader bexobrutide, gaining access to a promising drug.

Biotech & Genomic Medicine▲ · 1 stocks
Nurix Therapeutics Inc
NRIX
▲ PositiveCapitalrelevance

Wider net loss and lower revenue are negative, but the $700 million upfront from Roche deal and potential $2.3 billion total outweigh, with strong cash position.

© 2026 MarketDXNews